摘要
吉西他滨是治疗非小细胞肺癌一线方案的主要药物之一,但肿瘤对其原发或继发耐药常导致该药无效。研究表明核糖核苷酸还原酶、核苷转运蛋白、细胞质-5’-核苷酸酶-Ⅱ、c—Jun氨基末端激酶及微囊蛋白-1与吉西他滨耐药相关。
Gemcitabine is one of main first- line drugs in non- small cell lung cancer chemotherapy, but primary or secondary drug resistance often leads to be invalid. Studies indicate that ribonucleotide reductase, nueleoside transporters, Cytosolic 5 ' - nucleotidase Ⅱ , c-Jun NH2- terminal kinase and caveolin- 1 are associated with gemcitabine resistance.
出处
《国际肿瘤学杂志》
CAS
2009年第8期604-606,共3页
Journal of International Oncology
关键词
吉西他滨
癌
非小细胞肺
耐药
药物疗法
Gemcitabine
Carcinoma, non- small- cell lung
Drug resistance
Drug therapy